Abstract-A new scale for the potentiation was introduced and was termed pA1/2.
The value can be calculated by using an equation ; pA1/2=pAx + log(1/x-1), which is similar to that which is used for the calculation of pA2.
For the use of the equation, the parallel shift of the dose-response curve and the unchanged maximum response are prerequisites. This experiment showed the validity and the usefulness of calculating the pA1/2 values, in the biological assay.
In the assay of anticholinesterases, the potentiating effects of neostigmine or physostigmine on the acetylcholine-induced contraction were examined, by using frog's rectus abdominis. The pA1/2 values obtained in the presence of two different concentrations of anticholinesterases were the same, indicating that pA1/2 is a parameter which is specific to the potentiator. The potentiating effects of some cardenolides on the K-induced contracture were examined, by using the frog's ventricular muscles.
The relative potencies of four cardenolides obtained from the pA1/2 values well agreed with those reported earlier.
The amount of the cardenolides required for this assay was smaller than required for other methods.
The pA2 value has been widely used as an estimate of the potency of antagonistic drugs, since Schild proposed the pA concept (1) . This parameter means the affinity of the antagonist to the receptor. We have developed a new index for the potentiating agent from the pA concept, though the dose-ratios of the agonists are commonly used. The usefulness and the validity of the new index were examined in this study. A preliminary report of the results has been published (2).
Theoretical consideration: The principle for calculating a new index of the potentiating effect is as follows; it is an extension of the pA concept commonly used in a competitive antagonism of drugs. In order to obtain the pA2 value, it is required that the dose-response curve be shifted to the right in parallel without any change in the maximum response (3).
When these requirements are fulfilled, the antagonism is considered to be competitive, and the pA2 value indicates the affinity of antagonistic agent to the receptor. For the calculation of the pA2 value, the following equation is used; (1) where pAx is the negative logarithm of the dose of the antagonist used and x is the ratio of the dose of agonist in the presence of the antagonist to that in its absence. ET AL, Now, assume that the dose-response curve is shifted to the left in parallel without any change in the maximum response. This potentiation is just opposite to the competitive antagonism in the direction of the shift. Then, such a relationship similar to that of the competitive antagonism should hold between the shifted dose-response curve and the control curve. The index for the potentiator may arbitrarily be termed pAo which is the negative logarithm of the dose of the potentiator that requires a halving of the dose of the agonist to produce the same response as that in the absence of potentiator. For the calculation of the value of pA1/2, the equation 1 which gives the pA2 value will have to be converted to the following equation : (2) where x is the ratio of the dose of agonist in the presence of potentiator to that in its absence, A: The indices (pA1/2, pD2=the negative logarithm of ED50, pDc=the negative logarithm of the concentration in which systolic contracture was induced) and the relative potencies in each assay method.
Figures in parentheses are the 95 % confidence limits. B: The minimum concentrations (g/ml) of the compounds required for each assay method. Table 2 , as well as the smallest concentrations required for each method.
As can be seen, the 95 % confidence limits of the relative potencies were close to each other, indicating that the pA1/2 value is a useful indicator of the potentiating effect. Furthermore, the present method requires much lower concentrations of the compounds than the other two methods, indicating that it can be applied to the assay of compounds having lower potency or lower solubility. In this experiment, pA1/2 was revealed to be a useful parameter, which implies some specific property of the potentiator. 
.
When all these processes are present, the following equation can be obtained,
When processes I and II are present and process III is absent, i.e., agent C is absent,
To obtain the same responses in the presence and absence of agent C, the concentration of agonist A in the presence of agent C is required to be x times of that in the absence. Then, the following equation can be obtained, (6) .
If [B] T is much larger than KB,
If [B] T is just the same as KB, (8) .
If [B] T is much smaller than KB, the equation (4) does not differ from the equation (5) . In this experiment, the equation (7) may be more acceptable, since x can be smaller than 0.5.
Consequently,
